scispace - formally typeset
K

Krishna P. Kota

Researcher at United States Army Medical Research Institute of Infectious Diseases

Publications -  43
Citations -  1341

Krishna P. Kota is an academic researcher from United States Army Medical Research Institute of Infectious Diseases. The author has contributed to research in topics: Virus & Ebola virus. The author has an hindex of 20, co-authored 42 publications receiving 1172 citations. Previous affiliations of Krishna P. Kota include United States Department of the Army & PerkinElmer.

Papers
More filters
Journal ArticleDOI

Infectious Lassa Virus, but Not Filoviruses, Is Restricted by BST-2/Tetherin

TL;DR: The results demonstrate that BST-2 might be a broad antiviral factor with the ability to restrict release of a wide variety of human pathogens, however, at least filoviruses, RVFV, and CPXV are immune to its inhibitory effect.
Journal ArticleDOI

IFITM-2 and IFITM-3 but Not IFITM-1 Restrict Rift Valley Fever Virus

TL;DR: It is shown that interferon-induced transmembrane protein 1, IFITM-2, and IFITm-3 exhibit a broad spectrum of antiviral activity against several members of the Bunyaviridae family, including Rift Valley fever virus (RVFV), La Crosse virus, Andes virus, and Hantaan virus, all of which can cause severe disease in humans and animals.
Journal ArticleDOI

Identification of an antioxidant small-molecule with broad-spectrum antiviral activity

TL;DR: Small molecule chemical screening for Ebola virus inhibitors resulted in identification of a compound NSC 62914, which was found to exhibit anti-filovirus activity in cell-based assays and in vivo protected mice following challenge with Ebola or Marburg viruses.
Journal ArticleDOI

Identification of essential filovirion-associated host factors by serial proteomic analysis and RNAi screen

TL;DR: Host proteins involved in cell adhesion, cytoskeleton, cell signaling, intracellular trafficking, membrane organization, and chaperones were identified and potentially identifies host factors that can be targeted for antiviral drug development.